| 招商通知 | | --- | | 第三届全球手术机器人大会 | | 第二届全球医疗科技大会 | 2025年7月1日 ， 专 注胶囊内窥镜技术创新的医疗科技公司 CapsoVision, Inc.（纳斯达克代码：CV） ，宣布其 首次公开募股 （IPO） 定价为每股 5.00 美元，共发行 550 万股普通股，预计募资 约2750万美元（约合人民币2亿） 。 股票于 7 月 2 日在纳斯达克 资本市场开始交易。这次发行不仅是融资事件，更意味着这家专注胃肠道诊断创新的公司，正试图在全球医疗市场中占据更重要的位 置。 CapsoVision 的首席执行官 Dean Burns 在公司发布会上表示："从一开始，我们的目标就是让胶囊内窥镜不仅能看见，更能看全。今 天的 IPO，是让我们更接近这个愿景的重要一步。" # 市 场与竞 争环 境 全球胶囊内窥镜市场预计到 2030 年将达到 12 亿美元。推动这一市场发展的核心动力是人口老龄化、消化道疾病患病率上升，以及人 们对非侵入性检查方式的偏好。特别是在结直肠癌筛查领域，随着人们预防意识增强，非侵入式检测的需求愈加迫切。 然而，CapsoVision 面对的竞争也异 ...

Core Viewpoint - CapsoVision, Inc. has successfully completed its initial public offering (IPO) of 5,500,000 shares at a price of $5.00 per share, raising gross proceeds of $27.5 million before expenses [1][2]. Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI technologies for capsule endoscopy solutions [1][4]. - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel [4]. - The company is developing a pipeline product, CapsoCam Colon, aimed at non-invasive colon imaging and polyp detection, with plans to expand across multiple gastrointestinal indications [4]. IPO Details - The shares began trading on the Nasdaq Capital Market under the ticker symbol "CV" on July 2, 2025 [1]. - The underwriters have a 30-day option to purchase an additional 825,000 shares at the IPO price [1]. - The offering was managed by The Benchmark Company, LLC and Roth Capital Partners [2]. Regulatory Information - A registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025, allowing the offering to proceed [3].

Core Points - CapsoVision, Inc. has announced the pricing of its initial public offering (IPO) of 5,500,000 shares at $5.00 per share, with trading expected to begin on July 2, 2025 [1] - The offering is projected to generate gross proceeds of approximately $27.5 million before deducting underwriting discounts and commissions [2] - The company has granted underwriters a 30-day option to purchase an additional 825,000 shares at the IPO price [2] Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI technologies for capsule endoscopy solutions [1][4] - The flagship product, CapsoCam Plus®, is a wire-free capsule endoscope that provides high-resolution visualization of the small bowel [4] - The upcoming product, CapsoCam Colon, aims to facilitate non-invasive colon imaging and polyp detection, with plans to expand across various gastrointestinal indications [4]